Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04723095

Conditions

Cervical Large Cell Neuroendocrine Carcinoma

Cervical Neuroendocrine Carcinoma

Cervical Small Cell Carcinoma

Cervical Undifferentiated Carcinoma

Stage I Cervical Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Follow-Up

Medical Chart Review

Study Details

Brief summary:

This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.

Conditions

Cervical Large Cell Neuroendocrine Carcinoma

Cervical Neuroendocrine Carcinoma

Cervical Small Cell Carcinoma

Cervical Undifferentiated Carcinoma

Stage I Cervical Cancer AJCC v8

Study ID

NCT04723095

Start date

May 16, 2013

Status verified date

Mar, 2026

Completion date

Jan 1, 2044

Anticipated

Primary completion date

Jan 1, 2044

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:

  • Small cell neuroendocrine carcinoma
  • Large cell neuroendocrine carcinoma
  • Undifferentiated high-grade neuroendocrine carcinoma
  • Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
  • Patients with all stages of disease are considered eligible
  • Patients who do not speak English can be eligible if accompanied by an institutional interpreter
  • Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
  • Patient may be residents of any country and be of any ethnic background
  • Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website
  • Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate
  • Next of kin or legal authorized representatives of patients must read and speak English

Exclusion Criteria:

  • Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors

Study Design

Enrollment

750 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational (medical chart review)

Patients' medical records are reviewed retrospectively and prospectively. All prospective patients will be contacted via email, telephone, or U.S. Mail on case by case basis for up to 10 years to check status of disease and any further treatment received. Project staff can also access the patient's M. D. Anderson Epic medical record for updates. Request for additional clinic and treatment notes will be submitted to external medical institutions listed in the physician information form in order to access updated notes for non- M. D. Anderson patients.

Interventions

Follow-Up

Receive follow up

Medical Chart Review

Review of medical records

Primary outcome measure

  • Disease characterization data [ Time Frame: through study completion, an average of 1 year ]
  • Patient treatment data [ Time Frame: through study completion, an average of 1 year ]
  • Patient outcome data [ Time Frame: through study completion, an average of 1 year ]

Central Contacts and Locations

Central contacts

Larissa A. Meyer, MD

713-745-0973lmeyer@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Larissa A. Meyer, MD

713-745-0973lmeyer@mdanderson.org

Principal Investigator:

Larissa A. Meyer, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Mar 5, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-03-05.